Volume 24, Number 12—December 2018
Research Letter
Strongyloidiasis and Culture-Negative Suppurative Meningitis, Japan, 1993–2015
Table
Characteristic | All cases, no. (%), n = 37 | Culture-positive, no. (%), n = 14 | Culture-negative, no. (%), n = 23 |
---|---|---|---|
Demographic and clinical | |||
Sex | |||
M | 22 (59.5) | 9 (64.2) | 13 (56.5) |
F | 15 (40.5) | 5 (35.8) | 10 (43.5) |
Chief complaints | |||
Headache | 24 (64.9) | 6 (42.9) | 18 (78.3) |
Fever | 22 (59.5) | 9 (64.2) | 13 (56.5) |
Altered mental status | 8 (21.6) | 5 (35.7) | 3 (13.0) |
Nausea/vomiting | 8 (21.6) | 1 (7.1) | 7 (30.4) |
Immunocompromised status | |||
HTLV-1 infection† | 22 (71.0) | 8 (61.5) | 14 (77.8) |
Diabetes mellitus | 3 (8.1) | 2 (14.3) | 1 (4.3) |
Cirrhosis | 3 (8.1) | 3 (21.4) | 0 |
Steroid use | 4 (10.8) | 1 (7.1) | 3 (13.0) |
Strongyloidiasis infection type | |||
Nonsystemic strongyloidiasis | 14 (42.4) | 5 (35.7) | 9 (47.4) |
Hyperinfection | 3 (9.1) | 3 (21.4) | 0 |
Dissemination | 1 (3.0) | 0 | 1 (5.3) |
Not analyzed | 4 | 0 | 4 |
Died |
5 (13.5) |
3 (21.4) |
2 (8.7) |
CSF | |||
Neutrophils/mm3 | |||
500–2,999 | 24 (64.9) | 6 (42.9) | 18 (78.3) |
3,000–5,999 | 4 (10.8) | 1 (7.1) | 3 (13.0) |
6,000–9,999 | 2 (5.4) | 1 (7.1) | 1 (4.3) |
>10,000 | 3 (8.1) | 2 (14.3) | 1 (4.3) |
Glucose <40 mg/dL |
14 (37.8) |
7 (50.0) |
7 (30.4) |
Bacteriologic | |||
Blood culture | |||
Klebsiella pneumoniae | 7 (18.9) | 5 (35.7) | 2 (8.7) |
Streptococcus gallolyticus | 4 (10.8) | 4 (28.6) | 0 |
Escherichia coli | 3 (8.1) | 2 (14.3) | 1 (4.3) |
Streptococcus infantarius | 1 (2.7) | 1 (7.1) | 0 |
Campylobacter fetus | 1 (2.7) | 1 (7.1) | 0 |
Negative | 21 (56.8) | 1 (7.1) | 20 (87.0) |
CSF culture | |||
K. pneumoniae | 5 (35.7) | 5 (35.7) | 0 |
S. gallolyticus | 1 (7.1) | 1 (7.1) | 0 |
E. coli | 1 (7.1) | 1 (7.1) | 0 |
S. infantarius | 1 (7.1) | 1 (7.1) | 0 |
C. fetus | 1 (7.1) | 1 (7.1) | 0 |
Bacteroides fragilis | 1 (7.1) | 1 (7.1) | 0 |
*Patient median age (range): all, 60 y (19–91 y); culture-positive, 57 y (27–91 y); culture-negative, 58 y (19–90 y). CSF, cerebrospinal fluid; HTLV-1, human T-cell lymphotropic virus type 1.
†HTLV-1 serology results were available for 93% (13/14) of culture-positive patients and 78% (18/23) of culture-negative patients.
Page created: November 20, 2018
Page updated: November 20, 2018
Page reviewed: November 20, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.